Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A. Braun, Catherine J. Wu, Teddy Huang et al.|Cancer Cell|2021Cited by 515
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapySatyen H. Gohil, Kenneth J. Livak, J. Bryan Iorgulescu et al.|Nature Reviews Clinical Oncology|2020Cited by 286
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemiaNathaniel D. Anderson, Sara Ghorashian, Jack Birch et al.|Nature Medicine|2023Cited by 80
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐<scp>BCR</scp>inhibitor setting: a<scp>UK</scp>wide analysisToby A. Eyre, Amy A. Kirkwood, Satyen H. Gohil et al.|British Journal of Haematology|2019Cited by 79